Indivior Cuts Outlook Again as Rival Opioid Drug Eats Into Sales
This article is for subscribers only.
Indivior Plc plunged after lowering its sales guidance for the year again due to increasing competition to treat opioid addiction.
The British drugmaker said Thursday it now expects Sublocade’s net revenue for the year to be between $725 million and $745 million. The company was previously aiming for as much as $805 million, a target that had already been pared back.